,12–19 Two anti-IL17A monoclonal antibodies were approved for treatment of psoriasis, spondyloarthropathies, psoriatic arthritis, and ankylosing spondylitis,20 although both these antibody therapies had significant side effects. This evidence concerns the gene IL17A and psoriasis.